Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2 diabetes ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

A commission proposed a new definition of obesity focused on how excess fat affects the body, rather than assessing body mass index, that could change clinical care.

An international team of doctors proposed a new way to define obesity that's not based solely on BMI. Here's what they ...

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

21, 2025 — When children with obesity undergo weight-loss treatment, the effects have repercussions ... regardless of their body mass index, according to new ... Excess Weight Gain in First ...

The Lancet, a global medical journal that works with academics to identify issues in public health, hosted a Commission on Clinical Obesity on Jan. 16 in Baton Rouge to discuss a new approach to ...